Skip to main
ADUS

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare (ADUS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Addus HomeCare Corp has demonstrated impressive organic revenue growth post-pandemic, achieving a year-over-year increase of 12.3% in 2023, with sustained growth projections of 7.7% for 2024 and 7.4% year-to-date in 2025. The finalized increase of 2.6% in the Medicare Hospice rate for FY2026 presents a favorable regulatory environment that is likely to enhance revenue streams across its Hospice segment. Additionally, anticipated mergers and acquisitions (M&A) activity, combined with improvements from recent leadership changes, may further bolster operational efficiencies and revenue growth prospects.

Bears say

Addus HomeCare is facing challenges due to ongoing declines in same-store performance, attributed to Medicaid redeterminations that have created administrative bottlenecks, resulting in higher patient discharges relative to admissions. Approximately 97% of the company's segment revenues are affected by the current uncertainty surrounding the future Medicaid funding environment, exacerbated by the implications of the One Big Beautiful Bill Act (OBBBA). Despite its steady operational execution and favorable long-term demand outlook, the company's stock valuation appears disconnected from underlying earnings trajectory, leading to a negative outlook.

Addus HomeCare (ADUS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Addus HomeCare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Addus HomeCare (ADUS) Forecast

Analysts have given Addus HomeCare (ADUS) a Buy based on their latest research and market trends.

According to 9 analysts, Addus HomeCare (ADUS) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Addus HomeCare (ADUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.